SCHEMBL4910773

SCHEMBL4910773

CCCCc1ccc2c(c1N1CCOCC1)C(=O)NC2=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WEE1 P30291 3/20 0.38
TSHR P16473 1/20 0.37
STK10 O94804 1/20 0.36
SLK Q9H2G2 1/20 0.36
KMT2A Q03164 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
MAPT P10636 4/20 0.35
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
CHEK1 O14757 1/20 0.35
CAMK2B Q13554 2/20 0.35
CAMK2G Q13555 2/20 0.35
CAMK2D Q13557 2/20 0.35
CAMK2A Q9UQM7 2/20 0.35
CCNE2 O96020 1/20 0.35
CDK4 P11802 1/20 0.35
CCND1 P24385 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35
GSK3B P49841 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7986159 0.78 DHFR (0.42) MAPTGAA
SCHEMBL29614674 0.76 PARP1 (0.43) WEE1KMT2AMAPTALDH1A1KDM4E
SCHEMBL7983801 0.73 ALDH1A1 (0.42) KMT2ASMN1; SMN2ALDH1A1MEN1NPC1
SCHEMBL28988954 0.73 ELANE (0.43) KMT2AMAPTALDH1A1KDM4ECHEK1
SCHEMBL30352889 0.73 ELANE (0.43) KMT2AMAPTALDH1A1KDM4ECHEK1
SCHEMBL28597691 0.73 ELANE (0.40) SMN1; SMN2MAPTALDH1A1KDM4ECHEK1
SCHEMBL7986396 0.72 DRD4 (0.44) TSHRKMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL27468194 0.72 TNKS2 (0.46) TSHRKMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL28343053 0.72 ELANE (0.55) WEE1ALDH1A1KDM4ECHEK1CTRC
SCHEMBL6644399 0.71 HTR7 (0.37) ALDH1A1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275028-A1 Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof SIENA BIOTECH S.P.A. (IT) 2008-11-06 US disclosed
EP-1778658-A2 MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF Siena Biotech S.p.A. (IT) 2007-05-02 EP disclosed
WO-2006008133-A2 MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF SIENA BIOTECH S.P.A. (IT) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275028-A1 Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof CHRNA7, CHRNA5, CHRNA1 WEE1 4823/4885TSHR 521/4885STK10 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.